Following a public comment period, the Federal Trade Commission has approved a final consent order regarding Pfizer Inc.’s recent acquisition of Wyeth, and responses to members of the public who provided comments. The final order settles charges that the transaction as proposed would have been anticompetitive in a number of markets for animal vaccines and pharmaceutical products, and is designed to resolve those competitive issues.
The FTC vote approving the final order was 2-0, with Commissioners Pamela Jones Harbour and William E. Kovacic recused. (FTC File No. 091-0053; the staff contact is Kari A. Wallace, Bureau of Competition, 202-326-3085. See press release dated October 14, 2009, at http://www.ftc.gov/opa/2009/10/pfizer.shtm.)
Copies of the documents mentioned in this release are available from the FTC’s Web site at http://www.ftc.gov and from the FTC’s Consumer Response Center, Room 130, 600 Pennsylvania Avenue, N.W., Washington, DC 20580. Call toll-free: 1-877-FTC-HELP.
WASHINGTON — Today, the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC)…
WASHINGTON – Today, the U.S. Department of the Treasury and Internal Revenue Service (IRS) outlined…
WASHINGTON—Acting Senior Deputy Comptroller and Chief Counsel Ted Dowd today testified on the Office of…
The Committee convened in a closed session at the Department of the Treasury at 9:00…
WASHINGTON — Today, the Department of the Treasury is taking action to further degrade Russia’s…
WASHINGTON – The final results from the annual survey of foreign portfolio holdings of U.S. securities at…